Stephen Mahoney's most recent trade in Viridian Therapeutics Inc was a trade of 7,408 Common Stock done at an average price of $30.2 . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.19 per share. | 03 Mar 2026 | 7,408 | 33,349 (0%) | 0% | 30.2 | 223,648 | Common Stock |
| Viridian Therapeutics Inc | Stephen Mahoney | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 559,600 | 559,600 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Stephen Mahoney | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 111,900 | 111,900 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Stephen Mahoney | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 18,357 | 55,071 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Stephen Mahoney | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 18,357 | 40,757 (0%) | 0% | - | Common Stock | |
| Viridian Therapeutics Inc | Stephen Mahoney | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.32 per share. | 02 Mar 2026 | 7,627 | 33,130 (0%) | 0% | 29.3 | 223,624 | Common Stock |
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 440,565 | 440,565 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,428 | 73,428 | - | - | Restricted Stock Units | |
| Viridian Therapeutics Inc | Stephen Mahoney | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 23.33 per share. | 27 Sep 2024 | 21,400 | 21,400 (0%) | 0% | 23.3 | 499,262 | Common Stock |